Rxwire
In the news · 48h FDA 37 Eli Lilly 19 Roche 11 Merck & Co. (MSD) 9 Johnson & Johnson 5 Daiichi Sankyo 3 AbbVie 3 AstraZeneca 3
Trials & R&D · first seen 1h ago, updated 1h ago

Heard on the Street: There is areal opportunity for pill-form peptides to hit big pharma’s most profitable franchises

1 outlet

The real opportunity is pill-form peptides that could hit big pharma’s most profitable franchises.

Summary from WSJ - Health.

Coverage 1 article · 1 outlet

  1. WSJ - Health
    Heard on the Street: There is areal opportunity for pill-form peptides to hit big pharma’s most profitable franchises